Literature DB >> 29996130

Cost of Hospitalizations due to Exacerbation in Patients with Non-Cystic Fibrosis Bronchiectasis.

David de la Rosa Carrillo1, Annie Navarro Rolon2, Rosa Maria Girón Moreno3, Beatriz Montull Veiga4, Casilda Olveira Fuster5, Alicia Padilla Galo6, Concepción Prados Sánchez7, Esther Quintana Gallego8, Oriol Sibila Vidal9, Nuria Celorrio Jiménez10, Antonio Ruiz Peña11, Antoni Torres Martí12, Maria Jesús Avilés Inglés13, Marina Blanco Aparicio14, Marta García-Clemente15, Rafael Golpe Gómez16, Ainhoa Gómez Bonilla17, Cristina Gómez González18, Maria Victoria Leal Arranz19, Patricia Mínguez Clemente20, Belén López Muñiz21, Luis Máiz Carro22, Ana Pando Sandoval15, Juan Luis Rodríguez Hermosa23, Ane Uranga Echeverria24, Ana Núñez Ares25, Lorena López Roldán26, Carmen Abellán Martínez13, Abel Jesús Martínez García25, Francisco Javier Michel de la Rosa27, Raúl Godoy Mayoral28, Miguel Ángel Martínez-García4.   

Abstract

BACKGROUND: Knowing the cost of hospitalizations for exacerbation in bronchiectasis patients is essential to perform cost-effectiveness studies of treatments that aim to reduce exacerbations in these patients.
OBJECTIVES: To find out the mean cost of hospitalizations due to exacerbations in bronchiectasis patients, and to identify factors associated with higher costs.
METHODS: Prospective, observational, multicenter study in adult bronchiectasis patients hospitalized due to exacerbation. All expenses from the patients' arrival at hospital to their discharge were calculated: diagnostic tests, treatments, transferals, home hospitalization, admission to convalescence centers, and hospitals' structural costs for each patient (each hospital's tariff for emergencies and 70% of the price of a bed for each day in a hospital ward).
RESULTS: A total of 222 patients (52.7% men, mean age 71.8 years) admitted to 29 hospitals were included. Adding together all the expenses, the mean cost of the hospitalization was EUR 5,284.7, most of which correspond to the hospital ward (86.9%), and particularly to the hospitals' structural costs. The adjusted multivariate analysis showed that chronic bronchial infection by Pseudomonas aeruginosa, days spent in the hospital, and completing the treatment with home hospitalization were factors independently associated with a higher overall cost of the hospitalization.
CONCLUSIONS: The mean cost of a hospitalization due to bronchiectasis exacerbation obtained from the individual data of each episode is higher than the cost per process calculated by the health authorities. The most determining factor of a higher cost is chronic bronchial infection due to P. aeruginosa, which leads to a longer hospital stay and the use of home hospitalization.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Antibiotic treatment; Bronchiectasis; Costs; Hospitalization; Pseudomonas aeruginosa colonization

Mesh:

Year:  2018        PMID: 29996130     DOI: 10.1159/000489935

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  5 in total

1.  Prognosis-Based Early Intervention Strategies to Resolve Exacerbation and Progressive Lung Function Decline in Cystic Fibrosis.

Authors:  Neeraj Vij
Journal:  J Pers Med       Date:  2021-02-03

2.  Clinical features related to hospital expenses for non-cystic fibrosis bronchiectasis in China.

Authors:  Yanliang Ma; Daishun Liu; Yingqun Ji; Xuemei Wei; Dianzhu Pan; Fei Xu; Qingguo Di; Xiaoju Chen; Fengming Luo; Jiujin Zhang; Guiying Ou; Yan Zhang; Kaishu Li; Dong Zhang; Wanping Wang; Jinfu Xu; Jianying Li; Dan Zhu; Feng Tian; Manqi Fan
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

3.  Brazilian consensus on non-cystic fibrosis bronchiectasis.

Authors:  Mônica Corso Pereira; Rodrigo Abensur Athanazio; Paulo de Tarso Roth Dalcin; Mara Rúbia Fernandes de Figueiredo; Mauro Gomes; Clarice Guimarães de Freitas; Fernando Ludgren; Ilma Aparecida Paschoal; Samia Zahi Rached; Rosemeri Maurici
Journal:  J Bras Pneumol       Date:  2019-08-12       Impact factor: 2.624

4.  Prognostic performance of the FACED score and bronchiectasis severity index in bronchiectasis: a systematic review and meta-analysis.

Authors:  Min He; Min Zhu; Chengdi Wang; Zuohong Wu; Xiaofeng Xiong; Hongxia Wu; Deyun Cheng; Yulin Ji
Journal:  Biosci Rep       Date:  2020-10-30       Impact factor: 3.840

Review 5.  Autophagy Augmentation to Alleviate Immune Response Dysfunction, and Resolve Respiratory and COVID-19 Exacerbations.

Authors:  Garrett Pehote; Neeraj Vij
Journal:  Cells       Date:  2020-08-24       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.